Navigation Links
Researchers challenge previous findings regarding widely used asthma treatment
Date:1/10/2008

WINSTON-SALEM, N.C. A new study published recently in The Lancet reveals that one of the most commonly used asthma medicines -- long-acting beta-agonists -- may not be associated with adverse events in people based on their genotype (gene variation), as previous studies had shown.

The study analyzed the effects of long-acting beta-agonist therapy, used in combination with inhaled corticosteroids, in asthmatics who have a specific beta-2 adrenergic receptor (ADRB2) genotype.

Investigators analyzed data from two clinical trials performed by AstraZeneca Pharmaceuticals LP. In each trial, patients were randomized to receive one of two different long-acting beta-agonists. In the case of each of the therapies, asthma symptoms and control improved, but no differences were observed based on the ADRB2 genotype.

These results are extremely important because previous studies on short-acting beta-agonists showed evidence for an adverse genotypic effect, said Eugene R. Bleecker, M.D., Thomas H. Davis Professor of Medicine, co-director of Center for Human Genomics at Wake Forest Baptist, and lead-investigator for the study. Smaller studies on long-acting beta-agonists have produced conflicting results.

Current guidelines recommend the use of combination therapy, with long-acting beta-agonists and inhaled corticosteroids, to control moderate to severe persistent asthma.

With over 2,000 patients in this study receiving combination therapy, it was reassuring that no adverse safety effects could be attributed to an individuals genotype, said Bleecker.

Ten percent of the U.S. population suffers from asthma. Each year, approximately 4,000 people die with asthma as the underlying cause.


'/>"/>

Contact: Shannon Koontz
shkoontz@wfubmc.edu
336-716-2415
Wake Forest University Baptist Medical Center
Source:Eurekalert

Page: 1

Related medicine news :

1. UT Health Science Center researchers decoding saliva to detect breast cancer
2. Protein power: Researchers trigger insulin production in diabetic mice
3. Researchers use neuroimaging to study ESP
4. UGA researchers receive $9 million in grants to study barriers to effective addiction treatment
5. Researchers seek to make cavity-causing bacteria self-destruct
6. Human factors researchers test voting systems for seniors that can improve voting accuracy and speed
7. New research tools are too complex for easy answers, researchers say
8. In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment
9. U of M researchers discover fast-acting cyanide antidote
10. SLU researchers show how to stop muscle weakness caused by myasthenia gravis
11. Researchers solve first structure of a key to intact DNA inheritance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Monica, CA (PRWEB) , ... May 03, 2016 , ... ... the highest quality medical providers to build the leading network of doctors and therapists ... Eric Nepomnaschy, D.C., founder of the distinguished Bay Chiropractic and Rehabilitation in ...
(Date:5/3/2016)... ... May 03, 2016 , ... SELEX (systematic evolution ... from a random library of sequences depending on their attraction for a target ... SELEX selection is commonly performed using filters, panning, or affinity chromatography separations. However, ...
(Date:5/3/2016)... FL (PRWEB) , ... May 03, 2016 , ... ... leading innovative specialty pharmacies, will be represented at the 2016 Asembia Specialty ... Vegas. The Asembia Summit is the largest U.S. health care conference for the ...
(Date:5/3/2016)... ... May 03, 2016 , ... Boston Children’s Hospital today announced its ... situations or practice tricky or rare procedures in an environment that looks and feels ... is also available to inventors and “hackers” to develop and test new devices or ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... announces Benefits Alliance Insurance Services as the latest addition to its elite stable ... comprised of Partners Wayne Blasman, David Styles, and Paul Vincent. The Firm is ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016  In the next ten ... shift from systems dependent on CRTs monitors to those ... modality CRT Medical monitors and will automatically sync ... host of foreseeable benefits to this technological advancement, ... modalities have to be replaced in order to ...
(Date:4/29/2016)... 29, 2016 Glycotope GmbH, a ... announces the appointment of Dr. Alfredo Zurlo ... an oncologist with many years clinical experience and a ... His last role was at Mologen AG where he ... Board. Previously Dr. Zurlo held various positions at F ...
(Date:4/28/2016)... April 28, 2016 Research and ... Plastic Surgery Products Market 2016-2020" report to their ... , The global plastic surgery products market ... during the period 2016-2020. , ,The growing adoption of ... the growth of the market. Lasers are used to ...
Breaking Medicine Technology: